UMP HEALTHCARE HOLDINGS LIMITED (Incorporated in the Cayman Islands with limited liability) （於 開曼群島註冊成立的有限公 司） (Stock Code: 722) （股份代號：722） NOTIFICATION LETTER 通知信函 Dear Non-registered Holders (Note 1), As a Non-registered Holder, if you wish to receive Corporate Communications of the Company in electronic form, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares in the Company are held (collectively, the "Intermediaries") and provide ...

UMP HEALTHCARE HOLDINGS LIMITED (Incorporated in the Cayman Islands with limited liability) （於 司） 開曼群島註冊成立的有限公 (Stock Code: 722) （股份代號：722） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 24 March 2026 UMP HEALTHCARE HOLDINGS LIMITED (the "Company") – Notice of publication of Interim Report for the six months ended 31 December 2025 (the "Current Corporate Communication(s)") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at ...

Financial Performance - Revenue for the six months ended December 31, 2025, was HK$367,533,000, a decrease of 1.0% from HK$371,271,000 in 2024[14] - EBITDA for the same period was HK$45,623,000, down 2.0% from HK$46,552,000[14] - Profit before tax increased by 2.8% to HK$23,257,000 compared to HK$22,629,000 in the previous year[14] - Profit for the period rose by 5.0% to HK$20,217,000, up from HK$19,246,000[14] - Earnings per share increased by 4.9% to 2.36 HK cents from 2.25 HK cents[14] - Total consolidated revenue decreased by 1.0% from HK$371.3 million in 1H FY24/25 to HK$367.5 million in 1H FY25/26, primarily due to a decrease in revenue from clinical healthcare services in Hong Kong and Macau as well as Chinese Mainland[60] - Operating profit increased by 16.7% from HK$32.3 million in 1H FY24/25 to HK$37.7 million in 1H FY25/26, driven by significant growth in corporate healthcare solution services and clinical healthcare services in Hong Kong and Macau[56] - Other income and gains decreased by 21.5% from HK$6.5 million in 1H FY24/25 to HK$5.1 million in 1H FY25/26, primarily due to a decrease in dividend income from investments[62] - Net profit for 1H FY25/26 was approximately HK$20.2 million, an increase of 5.2% from HK$19.2 million in 1H FY24/25, attributed to reduced operating expenses[78] Assets and Liabilities - Total assets as of December 31, 2025, were HK$1,118,801,000, reflecting a 2.1% increase from HK$1,095,325,000[17] - Cash, bank balances, and deposits increased by 11.6% to HK$338,100,000 from HK$302,836,000[17] - Net current assets rose by 6.3% to HK$284,514,000 compared to HK$267,681,000[17] - Shareholders' funds increased slightly by 0.6% to HK$746,943,000 from HK$742,632,000[17] - Right-of-use assets amounted to HK$99.3 million as of December 31, 2025, up from HK$96.5 million on June 30, 2025[80] - The current ratio improved to 2.02 as of December 31, 2025, from 1.99 as of June 30, 2025, indicating strong liquidity[101] - The Group had free cash and bank deposits of approximately HK$336.3 million as of December 31, 2025, up from HK$301.1 million as of June 30, 2025[97] - The gearing ratio decreased to approximately 6.6% as of December 31, 2025, from 7.1% as of June 30, 2025[99] Operational Highlights - The Group focused on operational optimization and service digitalization, leading to lower staff costs and enhanced workflow efficiency[21] - The rollout of electronic pre-approval procedures significantly streamlined workflows, reducing turnaround time and improving accuracy in benefit verification[26] - The Group expanded collaboration with insurers in the Chinese Mainland, enhancing the reach of its cross-boundary care ecosystem[29] - The multi-disciplinary hub model was advanced, integrating various medical services into a single footprint, improving turnover efficiency and reducing infrastructure duplication[31] - AI-assisted tools in medical imaging were deployed to enhance diagnostic workflow quality and support clinicians[31] - The Group plans to enhance its digital transformation strategy by developing a one-stop mobile application for patients to manage appointments, access medical records, and receive personalized health insights[48] - The Group aims to strengthen its data analysis capabilities to support personalized interventions and risk assessments, while exploring AI-enabled tools to improve service quality and reduce administrative workload[48] Segment Performance - Corporate Healthcare Solutions in Hong Kong and Macau achieved revenue growth of 1.9% to HK$136.7 million, with operating profit rising 34.5% to HK$24.9 million[20] - Clinical Healthcare Services revenue was stable at HK$288.2 million, with operating profit increasing by 35.1% to HK$10.7 million[20] - The Chinese Mainland segment experienced a revenue decline of 4.5% to HK$19.1 million, with an operating profit of HK$2.1 million[20] - Total segment operating results increased by 16.7% to HK$37.7 million[20] Employee and Governance - The total number of full-time employees increased to 509 as of December 31, 2025, from 452 as of June 30, 2025[124] - Employee benefit expenses decreased by 5.7% from HK$96.1 million for 1H FY24/25 to HK$90.6 million for 1H FY25/26, representing about 24.7% of total revenue[70] - Professional service expenses increased by 0.3% from HK$133.5 million for 1H FY24/25 to HK$133.9 million for 1H FY25/26 due to improved operational efficiency[67] - The Board declared an interim dividend of HK$1.40 cents per ordinary share for the six months ended December 31, 2025, consistent with the interim dividend of HK$1.40 cents for FY24/25[135] - The Company has complied with the Corporate Governance Code during the six months ended December 31, 2025, maintaining high standards of corporate governance and transparency[138] Share Options and Directors - The Company adopted the 2023 Share Option Scheme on November 24, 2023, but has not granted any share options under this scheme since its adoption[132] - As of December 31, 2025, there were 11,200,000 share options outstanding under the Post-IPO Share Option Scheme, with no options granted, exercised, lapsed, or forfeited during the first half of FY25/26[132] - The total number of share options available for grant under the 2023 Share Option Scheme is 81,095,524 shares, representing approximately 10% of the issued shares as of the adoption date[185] - The total number of shares held by directors amounts to 378,986,659, which is approximately 46.73% of the issued shares[156] - Dr. Sun Yiu Kwong holds a total of 301,226,989 shares, representing approximately 37.14% of the company's shareholding[157] - The company appointed new directors effective from the conclusion of the annual general meeting on November 21, 2025[166]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯合醫務集團有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00722 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.001 | HKD | | 5,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.001 | HKD | | 5,000,000 | 本月底法定/ ...

Core Viewpoint - United Medical (00722.HK) reported a slight decline in revenue for the six months ending December 31, 2025, while showing a modest increase in profit attributable to shareholders [1] Financial Performance - Revenue for the period was approximately HKD 368 million, representing a year-on-year decrease of 1% [1] - Profit attributable to shareholders was HKD 18.392 million, reflecting a year-on-year increase of 2.5% [1] - Earnings per share stood at HKD 0.0236 [1] Dividend Announcement - The company proposed an interim dividend of HKD 0.014 [1]

Core Viewpoint - United Medical (00722) announced the appointment of Tang Muting as the authorized representative and legal document agent following the resignation of Zhang Zhihua for personal development reasons [1] Group 1 - Zhang Zhihua has resigned as the co-secretary of the company and will no longer serve as the authorized representative under the Hong Kong Stock Exchange Listing Rule 3.05, effective from February 25, 2026 [1] - Tang Muting will take over as the sole company secretary and has been appointed as the authorized representative and legal document agent to replace Zhang Zhihua, effective from February 25, 2026 [1]

Group 1 - The company announced the resignation of Mr. Zhang Zhihua as co-secretary and authorized representative effective from February 25, 2026, due to personal development reasons [1] - Ms. Tang Muting will assume the role of sole company secretary and has been appointed as the authorized representative and legal document agent to replace Mr. Zhang, effective from the same date [1]

Core Viewpoint - The company, United Medical (00722.HK), reported a steady performance despite a challenging macroeconomic environment, with a slight decline in revenue but an increase in profit for the first half of the 2025/26 fiscal year [1] Financial Performance - Revenue for the first half of the 2025/26 fiscal year was HKD 368 million, a year-on-year decrease of 1.0% [1] - EBITDA for the period was HKD 45.6 million [1] - Net profit recorded was HKD 20.2 million, reflecting a year-on-year growth of 5.0% [1] - Profit attributable to shareholders was HKD 18.4 million, an increase of 2.5% compared to the first half of the 2024/25 fiscal year [1] Market Conditions - The Hong Kong public healthcare system continues to face resource pressures and long waiting times, which has driven stable demand for private outpatient and diagnostic services [1] - An increase in medical insurance usage and higher employee medical premiums have supported activity levels in the private healthcare market [1] - Despite these positive factors, patient behavior remains cautious due to economic prudence [1] Operational Focus - The company is focusing on operational optimization and service digitization, which has led to a reduction in labor costs and improved process efficiency [1] - These efforts have helped maintain overall profitability stability, even with a slight decline in revenue [1]

Group 1 - The company, United Medical (00722), announced a mid-term dividend of HKD 0.014 per share to be distributed on April 15, 2026 [1]

Group 1 - The company reported a revenue of HKD 368 million for the six months ending December 31, 2025, representing a year-on-year decrease of 1% [1] - Profit attributable to the company's owners was HKD 18.392 million, reflecting a year-on-year increase of 2.47% [1] - Basic earnings per share were HKD 0.0236, and an interim dividend of HKD 0.014 was proposed [1] Group 2 - The decrease in total comprehensive income by 1.0% was primarily due to a reduction in clinical healthcare revenue from Hong Kong, Macau, and mainland China [1]